8-K: DIH Holding US, Inc. Announces Public Offering of Common Units

DIH Holding US, Inc. priced a public offering of 5,937,100 common units, each consisting of one share of Class A common stock and one Class A warrant, at a purchase price of $0.7832 per unit.

Summary

• DIH Holding US, Inc. announced the pricing of a public offering of 5,937,100 common units at $0.7832 per unit on January 31, 2025.
• Each unit includes one share of Class A common stock and one Class A warrant.
• The Class A warrants have an exercise price of $0.7832 per share and expire on February 3, 2030.
• The offering closed on February 3, 2025, with net proceeds of approximately $3.9 million after deducting placement agent fees and other expenses.
• The company intends to use the net proceeds for capital expenditures, working capital, and general corporate purposes.
• Maxim Group LLC served as the exclusive placement agent for the offering.
• The company entered into a warrant agency agreement with Continental Stock Transfer & Trust Company to act as warrant agent.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The company successfully raised capital, which is generally a positive sign. However, the offering involves dilution and carries inherent risks associated with forward-looking statements.

Positives

• The offering provides DIH Holding US, Inc. with approximately $3.9 million in net proceeds.
• The funds will be used for capital expenditures, working capital, and general corporate purposes, supporting the company's growth initiatives.

Negatives

• The offering involves dilution for existing shareholders due to the issuance of new shares and warrants.
• The company is subject to lock-up agreements restricting the issuance of additional shares for a period of 90 days.

Risks

• The company's intended use of proceeds is subject to change.
• Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.
• The company's directors, executive officers and holders of 5% or more of the company's outstanding shares of common stock have agreed for a period of six (6) months after the Offering is complete not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any shares of common stock or other securities convertible into or exercisable or exchangeable for common stock without the prior written consent of the Placement Agent in the case of the D&O Lock-Ups or the written consent of the Placement Agent and requisite number of investors in the Offering in the case of the Company Lock-Up, subject to certain exceptions.

Future Outlook

The company intends to use the net proceeds for capital expenditures related to its business and for working capital and general corporate purposes.

Industry Context

This announcement reflects a common capital-raising activity for companies seeking to fund operations and growth initiatives. The use of units, combining stock and warrants, is a structure often employed to attract investors.

Comparison to Industry Standards

• Comparable companies in the healthcare technology sector, such as Teladoc Health and Livongo Health (prior to its acquisition), have utilized public offerings to fund expansion and innovation.
• The terms of the offering, including the unit price and warrant exercise price, are within the typical range for similar offerings by companies of comparable size and stage of development.
• Placement agent fees of 7.0% are standard for best-efforts public offerings, although the reduced fee of 3.5% for certain investors is a negotiated incentive.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares and warrants.
• The company's employees may benefit from increased investment in the business.
• Customers may benefit from improved products and services resulting from the use of proceeds.

Next Steps

• The company will use the net proceeds for capital expenditures, working capital, and general corporate purposes.
• The company will need to manage the warrant overhang and potential dilution from warrant exercises.
• The company will need to comply with ongoing reporting requirements under the Exchange Act.

Key Dates